As a result of this therapeutic mode of action, DTP3 was highly effective in killing MM cell lines and primary cancer cells from MM patients in vitro, with far greater cancer cell specificity than IκBα kinase (IKK)β/NF-κB inhibitors. The gene discussed is NFKB1; the disease is Miyoshi myopathy.